Persistent PTC sees slim chances on DMD drug decrease further

Markets reacted accordingly on Tuesday as PTC Therapeutics (Nasdaq: PTCT) suffered the latest blow to its hopes to gain approval in the USA for Translarna (ataluren) as a treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

The US drugmaker saw its share price slide by 14% to $16.81 after the publication of an FDA report that raises concerns over the data submitted to show Translarna’s efficacy in nmDMD patients, who make up around 10 to 15% of those with DMD.

"Ultimately, no positive results from any prospectively planned analyses that are persuasive"